DIA Biosimilars 2013

SNBL Clinical

SNBL USA receives FDA letter declaring all issues resolved

Wednesday, November 14, 2012 10:24 AM

SNBL USA, an Everett, Wash.-based, wholly owned subsidiary of Shin Nippon Biomedical Laboratories, has received a formal close out letter from the FDA indicating that it has successfully resolved all the issues identified in an August 10, 2010, warning letter.

More... »

Cenduit: Now with Patient Reminders

Accelovance names chief medical officer

Monday, November 14, 2011 02:33 PM

Accelovance has named Stephan A. Bart Sr., M.D. chief medical officer. Bart will be responsible for medical affairs and site operations, focused on enhancing the level of clinical solutions Accelovance can provide to clients.

More... »

CRF Health – eCOA Forum

Crane joins SNBL USA

Monday, November 7, 2011 10:47 AM
SNBL USA has named Mark T. Crane vice president of business development. Crane will have overall responsibility for the company’s marketing, sales and business development efforts and will be tasked with driving the growth of SNBL USA's business model and fostering positive relationships with new and current customers.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs